Dhanak heads to Deciphera
Plus: Quirk takes on CEO role at Terns and an update from Structure
Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) said Dashyant Dhanak will succeed EVP and CSO Daniel Flynn, effective Sept. 5. Dhanak was CSO and EVP at Incyte Corp. (NASDAQ:INCY), having worked at Janssen Research & Development and GSK plc (LSE:GSK; NYSE:GSK). Flynn, who founded Deciphera, will transition to the role of senior adviser. The company also appointed Ron Squarer as chairperson, succeeding James Bristol, who will remain a board member. Squarer first joined the Deciphera’s board in 2019.
Terns Pharmaceuticals Inc. (NASDAQ:TERN) President and Head of R&D Erin Quirk is now CEO, following the resignation of Senthil Sundaram for health reasons. Sundaram also resigned from the company’s board, but will stay on with the company as a senior adviser. ...
BCIQ Company Profiles